The Q3 cluster shows conviction from active asset managers ahead of positive casdatifan data, but the October $250M equity offering at $17.50 (below the Q3 average cost) likely diluted these positions. Monitor Q4 13F filings to see if the buyers held or exited post-offering.
Drug in focus
RCUS drug pipeline →casdatifan
◆ Mixed Named in this fund cluster- Impact
- Phase
- Phase 2
- Time to market
- Estimated 3-5 years. The drug is in Phase 2; a Phase 3 registrational trial has not yet been initiated. Even with a potential accelerated path, FDA submission is likely several years away.
- Next catalyst
- None dated
What to watchWatch for the next ARC-20 data update at a medical conference (likely 2027) and any announcement of a Phase 3 registrational trial start. The $250M capital raise at a discount signals near-term cash needs despite positive data; monitor for further dilution risk. The stock is technically oversold (RSI 27.5) with strong analyst support, but no hard binary catalyst is scheduled within the next 12 months.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $18.95entry
- T+1 · 7d ago −1.48%α −1.11% · $18.67
- T+5 · 20h ago −11.03%α −9.34% · $16.86
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Five institutional investors added $9.8M in RCUS during Q3 2026, led by Aberdeen Group doubling its stake to $27.3M, while Citigroup trimmed $2.0M. The cluster follows positive casdatifan Phase 2 data and a $250M October equity offering, but the 45-day reporting lag means positions may have shifted since quarter-end.
Key Financial Metrics
Institutional Positions
Net institutional flow: $9.8M
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Aberdeen Group | ADD | +62.4% | $27.3M | $7.2M |
| Barclays | DOUBLED | +340.3% | $2.2M | $1.6M |
| Russell Investments Group | ADD | +65% | $3.5M | $961.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citigroup | TRIM | -49.9% | $3.5M | -$2.0M |
Key Facts
- 5 institutional buyers added net $9.8M in Q3 2026, 1 seller reduced $2.0M
- Aberdeen Group was the largest buyer, adding $7.2M to reach $27.3M (a 62.4% increase)
- Barclays more than quadrupled its position (+340.3%), adding $1.6M
- Citigroup trimmed 49.9% of its stake, reducing by $2.0M
- 13F data is 45+ days stale; the October equity offering and subsequent price action may have altered positions
- No open-market insider buying corroborates the cluster (confluence score 18/100)
Financial Impact
5 institutions accumulated $9.8M in net new positions while 1 institution reduced holdings by $2.0M
Risk Factors
- 13F data is stale by 45+ days; positions may have been unwound after the October equity offering
- No insider buying to corroborate the institutional signal
- Revenue declined 65% YoY in the most recent quarter due to the Gilead collaboration wind-down
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-RCUS-2026-Q3 |
Track record
13 reports on RCUS
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Viewing Entry $18.95 to $16.86 ▼ −11.03% −9.34% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 ▲ +0.45% −2.84% vs SPY
- Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 ▼ −2.42% −3.68% vs SPY
- Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 ▲ +1.89% +1.33% vs SPY
- Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 ▲ +3.87% +4.58% vs SPY
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 ▼ −3.87% −4.58% vs SPY
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 ▼ −23.62% −23.70% vs SPY
- Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 ▼ −7.88% −7.32% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 ▼ −7.79% −7.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers